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Abstract
We have investigated the mRNA amounts of six lysosomal proteins (L-hexosaminidase K- and L-subunit, sphingolipid
activator protein precursor, GM2 activator protein, lysosomal sialidase, L-glucocerebrosidase) involved in the degradation of
glycosphingolipids. We analyzed extracts from brain tissues of mouse models for lysosomal storage diseases, i.e., the GM2
gangliosidoses and the deficiency of the sphingolipid activator protein precursor (prosaposin). The mRNA levels were
quantified by real-time reverse transcription^polymerase chain reaction. Although storage of the respective lysosomal
proteins has been reported in human and mice, no increase of their mRNA amounts could be detected here. Our results
indicate that there is no transcriptional upregulation of lysosomal proteins in the examined neuronal storage
disorders. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Glycosphingolipids (GSL) are characteristic am-
phiphilic constituents of the outer lea£et of eukary-
otic plasma membranes [1]. Among them, ganglio-
sides, anionic GSL, are particularly abundant in
the nervous system [2,3]. The degradation of GSL
takes predominantly place in the lysosome by the
stepwise action of speci¢c acid exohydrolases (Fig.
1) (for review see [4,7]). Several of these enzymes
need the assistance of small glycoprotein cofactors.
These so-called ‘sphingolipid activator proteins’ (or
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(NeuAcK2C3)GalL1C4GlcL1C1Cer; RT, reverse transcrip-
tion; PCR, polymerase chain reaction; FAM, carboxy£uores-
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saposins) are the ganglioside GM2 activator protein
and the sphingolipid activator proteins A, B, C and
D (SAP A^D). The latter ones are generated through
proteolytic processing of a common precursor pro-
tein (pSAP or prosaposin).
Inherited defects of the hydrolytic enzymes cause
storage diseases in which intermediates of glycolipid
degradation accumulate in the lysosome (for review
see [5]). The GM2 gangliosidoses are characterized
by neuronal storage of ganglioside GM2 caused by
impaired enzymatic hydrolysis of GM2 by L-hexos-
aminidase (Hex; EC 3.2.1.52) or the absence of func-
tionally active GM2 activator protein. There are two
major forms of Hex: Hex A, composed of one K and
L subunit; and Hex B, composed of two L subunits.
However, only Hex A can act on the terminal Gal-
NAc residue of GM2. The storage of GM2 can
therefore be due to mutations in three di¡erent
genes: the L-hexosaminidase K-subunit gene, which
causes Tay^Sachs disease (variant B), the L-subunit
gene, which causes Sandho¡ disease (variant 0) and
the GM2 activator protein gene (variant AB) [6]. In
their infantile forms all three disorders display a sim-
ilar clinical phenotype and neuropathology except
that Sandho¡ disease is also associated with visceral
organ pathology. Mutations in the sphingolipid acti-
vator proteins A^D result in disorders mimicking the
respective enzyme de¢ciencies [7]. Two cases of a
complete pSAP de¢ciency have been described in
one family [8,9]. None of the SAPs were detected
in the tissues and abnormal accumulation of multiple
sphingolipids were noted in brain and systemic or-
gans. The sibs were shown to be homoallelic for a
mutation in the initiation codon of the pSAP tran-
script [10].
In addition to the storage of the lipid substrate of
the mutated protein, accumulation of lysosomal pro-
teins involved in the degradation of GSL has been
reported in various sphingolipidoses. Sandho¡ et al.
detected severalfold increases of activities of lysoso-
mal hydrolases in brain tissues of all three variant
forms of GM2 gangliosidosis [11]. Di¡erent tissues
(brain, liver, kidney) of patients with variant B or 0
were found to contain elevated levels of the GM2
activator protein [12]. Those ¢ndings suggest a regu-
latory pathway in the pathologically altered cells
which may lead to an increased biosynthesis of lyso-
somal hydrolases or activator proteins, depending on
the missing protein. This would be a compensatory
mechanism triggered by the storage of lipids, by
which the cell would try to escape from storage by
increased synthesis of catabolic enzymes.
Generation of mouse models for all three variant
forms of GM2 gangliosidoses and pSAP de¢ciency
by targeted disruption of the respective gene have
been previously described (for review see [13,14]).
Those knock-out mice, being all of the same genetic
background, are valuable tools for studying the
pathogenesis of these lysosomal storage diseases.
To address the question of whether the accumulation
of lysosomal proteins in GM2 gangliosidoses and
pSAP de¢ciency is due to transcriptional regulation,
we analyzed the mRNA levels of these proteins in
brain tissues of the respective mouse models. Since
the accumulation of lipids occurs in an age depen-
dent manner we analyzed mice of di¡erent ages in
order to examine a potential dependence of tran-
scriptional control on the degree of lipid storage.
For measuring gene expression we used real-time
quantitative RT^PCR which has been previously de-
scribed [15].
Fig. 1. Degradation pathway of some glycosphingolipids. The
respective acid hydrolases and activator proteins are indicated
for each degradation step. The lysosomal sphingolipid storage
disorders resulting from either enzyme or activator protein de¢-
ciency are shown in frames (adapted, with kind permission,
from [30]).
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2. Materials and methods
2.1. Animals
The generation of the knock-out mice has been
described [16^21]. Genotypes were determined by
the polymerase chain reaction (PCR).
2.2. RNA extraction
Isolated brain tissues were immediately frozen in
liquid nitrogen and stored at 380‡C until use. Total
RNA extraction was performed using TRIreagent
(Sigma, Deisenhofen, Germany) as described. RNA
samples were treated with RNase free DNase I
(Roche, Mannheim, Germany). The total RNA con-
tent was quanti¢ed by UV-spectrophotometry.
2.3. cDNA synthesis
The target RNA (50 ng or 250 pg for quanti¢ca-
tion of 18S rRNA, respectively) was reverse tran-
scribed using 12.5 U MuLV RT (PE Biosystems,
Weiterstadt, Germany) at 48‡C for 30 min in the
presence of 10 mM Tris^HCl (pH 8.3), 5 mM KCl,
200 WM dNTPs (each), 5 U RNasin (Promega, Hei-
delberg, Germany). Concentration of reverse primers
and MgCl2 was di¡erent for each speci¢c assay due
to optimization steps prior to quanti¢cation. After
cDNA synthesis, reverse transcriptase was denatu-
rated at 95‡C for 5 min.
2.4. Primers and probes
PCR primers and £uorogenic probes for all target
genes were designed using the computer program
Primer Express (PE Biosystems, Weiterstadt, Ger-
many). Primers were purchased from Gibco BRL,
Karlsruhe, Germany. All £uorogenic probes (PE
Biosystems) contained the reporter dye FAM cova-
lently attached to the 5P end and the quencher dye
TAMRA covalently attached to the 3P end. Exten-
sion from 3P end was blocked by attachment of a
3P phosphate group.
The speci¢city of the primers was analyzed by aga-
rose gel electrophoresis where a single product of
correct size could be observed for each primer pair.
2.5. PCR ampli¢cation
PCR reactions were performed in the ABI Prism
7700 sequence detection system.
Ten Wl from a total volume of 20 Wl from each
cDNA sample was analyzed in a total volume of
30 Wl containing 10 mM Tris^HCl (pH 8.3), 5 mM
KCl, 200 WM dATP, dCTP, dGTP and 400 WM
dUTP, 100 nM £uorogenic probe (Table 1), 0.75 U
AmpliTaqGold (PE Biosystems) and 0.075 U Uracil-
N-glycosylase (Roche). The concentration of MgCl2,
forward and reverse primer di¡ered for each detec-
tion of the respective mRNA due to optimization
steps prior to quanti¢cation.
Each PCR ampli¢cation was performed in dupli-
cate, using the following conditions: 2 min at 50‡C
and 10 min at 94‡C, followed by a total of 40 two-
Table 1
Sequences of primers and probes used for real-time RT^PCR
(m)RNA species Forward primer Reverse primer Probe
18S rRNA (X00686) GCATGGCCGTTCTTAGTTGG TGAACGCCACTTGTCCCTCT CCGATAACGAACGAGACTCTGCATGC
K-Subunit L-hexosaminidase
(X64331)
GGCCCTGACTGGAAGGACAT TGGTGCTGTCCACATACTCTCC CAGAGCCTTCTGTTCAGGCGTACCATGAA
L-Subunit L-hexosaminidase
(Y00964)
TGATAAGGTGGAGCTTCAGCC CCAAGGAGCAGAAAGGATGG CAAGTCACAGGCTCTGGCTTCCCTG
GM2 activator (L19526) GGCAAGACCAGCGTTCCC CAGCCACTTCCTTCTCCACG TCACTGCTCCTCAGAAGGTGGAGCTCAC
SAP precursor (U57999) TGCTGTACCCTCAGGATCACC GGACATCAGACACCAGCTTCAT CCAACCTAAGCTAACGAGGACGTCTGC
Lysosomal sialidase (U93702) CCTACGAGCTTCCAGATGGC CTGCGGAGGACGATCCTG CCGGAACCAGAATAACTACCATTGCCG
L-Glucocerebrosidase
(M24119)
GGTCCGCAACTTTGTCGATAG CCACCAACGCCACTCTCTG CAGCCCATGTTCTACCATCTTGGCCA
The GenBank accession numbers of the seven targets are indicated in brackets. All £uorogenic probes contained £uorescent dyes 5P
FAM and 3P TAMRA, extension from 3P and was blocked by attachment of a 3P phosphate group.
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temperature cycles (15 s at 94‡C and 1 min at
59‡C).
3. Results
In several neuronal lipid storage disorders, accu-
mulation of proteins in lysosomes has been reported.
In order to examine the transcriptional control of the
genes encoding the accumulated proteins, we quanti-
¢ed their respective transcripts in brain tissues of
mouse models for sphingolipidoses. Total RNA
was isolated from brain tissues of Tay-Sachs-
(HEXA(3/3)-), Sandho¡-(HEXB(3/3)-), variant
AB-(GM2AP(3/3)-) and pSAP(3/3)-mice and their
wild-type littermates of the same genetic background.
We quanti¢ed transcripts encoding the K- and L-sub-
unit of L-hexosaminidases, the GM2 activator pro-
tein, the SAP precursor, the L-glucocerebrosidase
and the lysosomal sialidase.
Detection of mRNA levels was achieved by real-
time RT^PCR. The sequences of the di¡erent prim-
ers and £uorogenic probes used for the RT^PCR are
presented in Table 1.
For correction of minor variations in input
amounts of RNA samples, mRNA levels were nor-
malized to the amount of 18S ribosomal RNA which
was quanti¢ed in parallel in each experiment.
The mRNA levels obtained for the respective wild-
type mice of the same age as the knock-out mice are
set at 1. The amounts of each transcript in the brain
tissues of knock-out mice are presented as ‘relative
fold induction’ as depicted in Fig. 2.
Quanti¢cation of the respective transcripts was
performed in total RNA extractions from brain tis-
sues of 20-day- and 7-month-old HEXA(3/3) mice.
An increase of any of the analyzed transcripts was
not observed. In contrast, we detected a 50% de-
crease of GM2 activator protein mRNA in brain
tissue of 20-day-old HEXA(3/3) mice.
Fig. 2. mRNA levels in brain tissues of HEXA(3/3)-, HEXB(3/3)-, GM2AP(3/3)-mice (a) and pSAP(3/3)-mice (b). The amounts
of the respective mRNAs are normalized to 18S rRNA. The mRNA levels obtained for the respective wild-type mice of the same age
as the knock-out mice are set at 1. The amounts of each transcript are presented as relative fold. The reproducibility of the results
shown above was con¢rmed in three individual experiments. HEXA, L-hexosaminidase K-subunit; HEXB, L-hexosaminidase L-sub-
unit; GM2AP, GM2 activator protein; pSAP, sphingolipid activator protein precursor; l. sialidase, lysosomal sialidase; GlcCerase,
L-glucocerebrosidase. *Not detected. No transcripts of the disrupted genes are present in the knock-out mice tissues, as has been pre-
viously described [16,19^21].
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We analyzed total RNA from brain tissue of 20-
day- and 3-month-old HEXB(3/3) mice. With re-
spect to the standard deviation, no signi¢cant di¡er-
ence between the mRNA levels of 20-day-old
HEXB(3/3) and wild-type mice was detected. In
3-month-old HEXB(3/3) mice a 2-fold increase of
the mRNA encoding the K-subunit of L-hexosamin-
idases was observed.
Furthermore, the respective transcripts were quan-
ti¢ed in total RNA of brain tissues of 20-day- and 6-
month-old GM2AP(3/3) mice. Again, no increase
of mRNA levels was observed at any age. We de-
tected a decrease of the mRNA encoding the L-sub-
unit of L-hexosaminidases (360%), the lysosomal
sialidase (360%) and the SAP precursor (370%), in
20-day-old GM2AP(3/3) mice.
Initial characterization of SAP precursor de¢cient
mice exhibited two distinct phenotypes with a dispro-
portionate high percentage of pSAP(3/3) dying in
utero or neonatally [21]. Those mice that survive the
neonatal period die around 30^35 days. In this study,
we analyzed total RNA of brain tissues from 1-day-
old and 30-day-old pSAP(3/3) mice.
No di¡erences between the respective mRNA lev-
els in pSAP(3/3) and their wild-type littermates
could be detected at any age (Fig. 2).
4. Discussion
To investigate whether the accumulation of certain
lysosomal proteins in lipid storage disorders is due to
a transcriptional regulation of their respective genes
we quanti¢ed mRNAs encoding proteins of glyco-
sphingolipid catabolism in brain tissues of animal
models for sphingolipidoses, all having the same ge-
netic background.
Quanti¢cation of transcripts was achieved by
quantitative real-time RT^PCR using a £uorogenic
5P exonuclease assay [15,22]. This method combines
PCR ampli¢cation and product detection in one sin-
gle step. Since this technique allows quanti¢cation of
PCR products in the exponential phase of the reac-
tion where the e⁄ciency is high, very reproducible
results are obtained. Analysis of PCR product for-
mation was performed by relative quanti¢cation.
Previous work has demonstrated the linearity of
real-time PCR and detailed the use of standard
curves for relative quanti¢cation of gene targets
[23]. The speci¢cation of the instrument used for
quanti¢cation guarantees a detection of twofold dif-
ferences in template amounts. Our results indicate
that di¡erences even smaller than factor two are de-
tected with high reproducibility.
The mRNA encoding the GM2 activator protein is
reduced to 50% in 20-day-old HEXA(3/3) mice
when compared with their wild-type littermates.
Since no storage of GM2 can be detected in 20-
day-old HEXA(3/3) mice, no correlation can be
made between lipid storage and the reduced
mRNA level of the GM2 activator protein [20].
The decrease may be due to a co-regulation of the
mRNAs encoding the K-subunit of L-hexosaminidase
and the GM2 activator protein that has been re-
ported earlier [24].
An increase of GM2 activator protein in brain
extracts of HEXB(3/3) but not HEXA(3/3) mice
has been observed (F. Platt, personal communica-
tion). Since we can show here that the mRNA
amount encoding the GM2 activator protein in
HEXB(3/3) mice is not increased, the accumulation
of the activator protein in these mice cannot be
caused by transcriptional regulation.
In brain tissues of 3-month-old HEXB(3/3) mice
a 2-fold increase of the mRNA encoding the K-sub-
unit of L-hexosaminidases was observed. This is the
only detectable signi¢cant increase of mRNA
amount in this study. However, the over-expression
of proteins observed in several lysosomal storage dis-
orders (if regulated at a transcriptional level) would
be expected to be caused by an increase in mRNA
amount of greater than 2-fold. For example, Baner-
jee et al. detected a 11-fold increase of GM2 activa-
tor protein in brain tissues of Tay^Sachs disease pa-
tients [12]. Morimoto et al. were able to detect a
massive accumulation of SAPs in several lysosomal
storage diseases with a striking 80-fold increase of
SAP-A in Tay^Sachs and Sandho¡ disease brains
[25].
In brain tissues of GM2AP(3/3)- and pSAP-
(3/3)-mice there was also no increase in mRNA
levels of any of the lysosomal proteins analyzed.
There is no signi¢cant increase of lysosomal sialidase
mRNA in 6-month-old GM2AP(3/3) mice (1.7-
fold) considering the standard deviation.
In this study we demonstrate that there is no cor-
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relation between the reported accumulation of pro-
teins and their respective mRNA levels in the brain
tissues of the sphingolipidosis mouse models. It must
be taken into consideration that the HEXA(3/3)-
and GM2AP(3/3)-mice display a di¡erent clinical
phenotype than the respective human diseases due
to an alternative degradation pathway of GM2 in
mice [26]. However, the HEXB(3/3)- and
pSAP(3/3)-mice closely resemble the human dis-
eases, and accumulation of proteins has been re-
ported in these mice ([21]; F. Platt, personal commu-
nication).
The reported accumulations have to occur for rea-
sons other than transcriptional regulation. One ex-
planation could be a defect degradation pathway of
those proteins in the pathologically altered acidic or-
ganelles. The hydrophobic proteins of lipid catabo-
lism could form insoluble aggregates induced by the
high concentration of lipids stored in the lysosomes.
This hypothesis is supported by the observations
made in another group of lysosomal storage dis-
eases: the neuronal ceroid-lipofuscinoses (NCL)
(for review see [27]). These inherited neurodegenera-
tive disorders have in common the accumulation of
auto£uorescent hydrophobic storage material in ly-
sosomes which consists of proteins and lipids for the
most part. In infantile NCL, sphingolipid activator
proteins A and D are the predominant proteins in
the storage material [28]. The subunit c of mitochon-
drial ATP synthase has been identi¢ed as the major
component of storage material in the other forms
(late infantile, juvenile and adult) of NCL. The ac-
cumulation of this protein seems to be due to its
hydrophobic character and tendency to self-aggre-
gate [29].
The aggregation of hydrophobic proteins in neu-
rodegenerative diseases seems to be a common fea-
ture. Our results indicate that the accumulation of
proteins in storage disorders seems to be a secondary
phenomenon which cannot be explained by a feed
back control of the transcription triggered by the
storage of lipids. A non-speci¢c trapping mechanism,
instead of a speci¢c transcriptional regulation, would
be consistent with the extremely high accumulation
of SAPs in Tay^Sachs and Sandho¡ disease because
SAPs do not directly participate in the degradation
of the stored lipid species in these disorders. Even
with a non-speci¢c mechanism, the quantities of the
accumulated lysosomal proteins are large enough to
implicate them in the neuronal pathology of the dis-
orders. However, based on the results described here,
other regulatory mechanisms involved in the regula-
tion of protein levels cannot be excluded. In addition
to a change in the amounts of transcripts a regula-
tion at the translational level must be taken into
consideration. However, since a dramatic accumula-
tion of SAP-A only, but not all four saposins origi-
nating from one single precursor in Tay^Sachs and
Sandho¡ disease have been found, protein deposition
seems to be a rather unspeci¢c phenomenon which is
unlikely to be regulated on translational level [25].
Unfortunately, there are no data available on protein
turnover of the speci¢c proteins analyzed here nei-
ther in normal cells nor in the pathologically altered
cells of lysosomal storage diseases. Analysis of trans-
lation rates and, in addition, studies on the proteases
involved in the degradation of lysosomal proteins
should provide further insight into the mechanism
of accumulation of the proteins studied here.
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